Blood products company Haemonetics (NYSE: HAE) will be reporting earnings this Thursday before market open. Here’s what to expect.
Haemonetics beat analysts’ revenue expectations last quarter, reporting revenues of $339.4 million, up 5.6% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ organic revenue estimates and a beat of analysts’ EPS estimates.
Is Haemonetics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Haemonetics’s revenue to grow 5.4% year on year, a reversal from the 5.3% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Haemonetics rarely misses Wall Street’s revenue estimates.
Looking at Haemonetics’s peers in the medical devices & supplies - specialty segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Inspire Medical Systems’s revenues decreased 7.9% year on year, beating analysts’ expectations by 1.1%, and Bausch + Lomb reported revenues up 7.3%, in line with consensus estimates. Inspire Medical Systems traded down 7.8% following the results while Bausch + Lomb was up 15.8%.
Read our full analysis of Inspire Medical Systems’s results here and Bausch + Lomb’s results here.
There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 2.8% on average over the last month. Haemonetics is up 14.9% during the same time and is heading into earnings with an average analyst price target of $124.50 (compared to the current share price of $120.29).
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
